Evidence map›Paper›PMID 39697450›Full record

ReviewWorld journal of transplantation2024

New frontiers in retinal transplantation.

Francesco Saverio Sorrentino, Patrick Di Terlizzi, Francesco De Rosa, Carlo Salati, Leopoldo Spadea, Caterina Gagliano, Mutali Musa, Marco Zeppieri

Abstract readReview
In one paragraph

Review in World journal of transplantation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Monitoring Gene Expression in Retina with synthetic serum markers.bioRxiv : the preprint server for biology · 2026
    Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Francesco Saverio SorrentinoDepartment of Surgical Sciences, Unit of Ophthalmology, Ospedale Maggiore, Bologna 40100, Italy.
Patrick Di TerlizziDepartment of Surgical Sciences, Unit of Ophthalmology, Ospedale Maggiore, Bologna 40100, Italy.
Francesco De RosaDepartment of Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori", Meldola 47014, Italy.
Carlo SalatiDepartment of Ophthalmology, University Hospital of Udine, Udine 33100, Italy.
Leopoldo SpadeaEye Clinic, Policlinico Umberto I, "Sapienza" University of Rome, Rome 00142, Italy.
Caterina GaglianoDepartment of Medicine and Surgery, University of Enna "Kore", Enna 94100, Italy.
Mutali MusaDepartment of Optometry, University of Benin, Benin 300283, Nigeria.
Marco ZeppieriDepartment of Ophthalmology, University Hospital of Udine, Udine 33100, Italy. mark.zeppieri@asufc.sanita.fvg.it.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

New frontiers about retinal cell transplantation for retinal degenerative diseases start from the idea that acting on stem cells can help regenerate retinal layers and establish new synapses among retinal cells. Deficiency or alterations of synaptic input and neurotrophic factors result in trans-neuronal degeneration of the inner retinal cells. Thus, the disruption of photoreceptors takes place. However, even in advanced forms of retinal degeneration, a good percentage of the ganglion cells and the inner nuclear layer neurons remain intact. This phenomenon provides evidence for obtaining retinal circuitry through the transplantation of photoreceptors into the subretinal region. The eye is regarded as an optimal organ for cell transplantation because of its immunological privilege and the relatively small number of cells collaborating to carry out visual activities. The eyeball's immunological privilege, characterized by the suppression of delayed-type hypersensitivity responses in ocular tissues, is responsible for the low rate of graft rejection in transplant patients. The main discoveries highlight the capacity of embryonic stem cells (ESCs) and induced pluripotent stem cells to regenerate damaged retinal regions. Recent progress has shown significant enhancements in transplant procedures and results. The research also explores the ethical ramifications linked to the utilization of stem cells, emphasizing the ongoing issue surrounding ESCs. The analysis centers on recent breakthroughs, including the fabrication of three-dimensional retinal organoids and the innovation of scaffolding for cell transportation. Moreover, researchers are currently assessing the possibility of CRISPR and other advanced gene editing technologies to enhance the outcomes of retinal transplantation. The widespread use of universally recognized safe surgical and imaging methods enables retinal transplantation and monitoring of transplanted cell growth toward the correct location. Currently, most therapy approaches are in the first phases of development and necessitate further research, including both pre-clinical and clinical trials, to attain favorable visual results for individuals suffering from retinal degenerative illnesses.

Indexed as

Human embryonic stem cellsPluripotent stem cellsRetinal stem cellRetinal tissue transplantRetinal transplantation

Identifiers

PMID39697450
PMCPMC11438945

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.